US 12,391,756 B2
Binding molecule specific for CD39 and use thereof
Qinghao Liu, Beijing (CN); Wenlai Zhou, Beijing (CN); Haiyan Yang, Beijing (CN); Hongling Wang, Beijing (CN); and Yajing Wang, Beijing (CN)
Assigned to JACOBIO PHARMACEUTICALS CO., LTD., Beijing (CN)
Appl. No. 17/774,170
Filed by JACOBIO PHARMACEUTICALS CO., LTD., Beijing (CN)
PCT Filed Nov. 4, 2020, PCT No. PCT/CN2020/126351
§ 371(c)(1), (2) Date May 4, 2022,
PCT Pub. No. WO2021/088838, PCT Pub. Date May 14, 2021.
Claims priority of application No. PCT/CN2019/115505 (WO), filed on Nov. 5, 2019.
Prior Publication US 2022/0411498 A1, Dec. 29, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01)] 20 Claims
 
1. An antibody or antigen-binding fragment thereof comprising a heavy chain variable region that comprises sequences of HCDR1, HCDR2, HCDR3; and a light chain variable region that comprises sequences of LCDR1, LCDR2, LCDR3, wherein:
(a) the HCDR1 comprises an amino acid sequence of SEQ ID NO: 5;
(b) the HCDR2 comprises an amino acid sequence of SEQ ID NO: 6;
(c) the HCDR3 comprises an amino acid sequence of SEQ ID NO: 7;
(d) the LCDR1 comprises an amino acid sequence of SEQ ID NO: 10;
(e) the LCDR2 comprises an amino acid sequence of SEQ ID NO: 59 or 11; and
(f) the LCDR3 comprises an amino acid sequence of SEQ ID NO: 12.